Literature DB >> 12372407

Molecular model of cyclin-dependent kinase 5 complexed with roscovitine.

Walter Filgueira de Azevedo1, Renato Tadeu Gaspar, Fernanda Canduri, João Carlos Camera, Nelson José Freitas da Silveira.   

Abstract

Here is described a structural model for the binary complex CDK5-roscovitine. Roscovitine has been shown to potently inhibit cyclin-dependent kinases 1, 2 and 5 (CDK1, 2, and 5), and the structure of CDK2 complexed with roscovitine has been reported; however, no structural data are available for complexes of CDK5 with inhibitors. The structural model indicates that roscovitine strongly binds to the ATP-binding pocket of CDK5 and structural comparison of the CDK2-roscovitine complex correlates the structural differences with differences in inhibition of these CDKs by this inhibitor. This structure opens the possibility of testing new inhibitor families, in addition to new substituents for the already known lead structures of adenine derivatives.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12372407     DOI: 10.1016/s0006-291x(02)02352-5

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  Study of the inhibition of cyclin-dependent kinases with roscovitine and indirubin-3'-oxime from molecular dynamics simulations.

Authors:  Bing Zhang; Vincent B C Tan; Kian Meng Lim; Tong Earn Tay; Shulin Zhuang
Journal:  J Mol Model       Date:  2006-06-13       Impact factor: 1.810

2.  Molecular models of protein kinase 6 from Plasmodium falciparum.

Authors:  Karisa Karla Manhani; Helen Andrade Arcuri; Nelson José Freitas da Silveira; Hugo Brandão Uchôa; Walter Filgueira de Azevedo; Fernanda Canduri
Journal:  J Mol Model       Date:  2005-11-04       Impact factor: 1.810

3.  Molecular dynamics simulations on the inhibition of cyclin-dependent kinases 2 and 5 in the presence of activators.

Authors:  Bing Zhang; Vincent B C Tan; Kian Meng Lim; Tong Earn Tay
Journal:  J Comput Aided Mol Des       Date:  2006-10-13       Impact factor: 3.686

4.  Cyclin-dependent kinase activity is required for progesterone receptor function: novel role for cyclin A/Cdk2 as a progesterone receptor coactivator.

Authors:  Ramesh Narayanan; Abayomi A Adigun; Dean P Edwards; Nancy L Weigel
Journal:  Mol Cell Biol       Date:  2005-01       Impact factor: 4.272

5.  Inhibition of Cdk5 increases osteoblast differentiation and bone mass and improves fracture healing.

Authors:  Mubashir Ahmad; Benjamin Thilo Krüger; Torsten Kroll; Sabine Vettorazzi; Ann-Kristin Dorn; Florian Mengele; Sooyeon Lee; Sayantan Nandi; Dilay Yilmaz; Miriam Stolz; Naveen Kumar Tangudu; David Carro Vázquez; Johanna Pachmayr; Ion Cristian Cirstea; Maja Vujic Spasic; Aspasia Ploubidou; Anita Ignatius; Jan Tuckermann
Journal:  Bone Res       Date:  2022-04-06       Impact factor: 13.567

6.  Cytotoxic activity and apoptosis-inducing potential of di-spiropyrrolidino and di-spiropyrrolizidino oxindole andrographolide derivatives.

Authors:  Sumit Kumar Dey; Dipayan Bose; Abhijit Hazra; Subhendu Naskar; Abhishek Nandy; Rudra Narayan Munda; Subhadip Das; Nabanita Chatterjee; Nirup Bikash Mondal; Sukdeb Banerjee; Krishna Das Saha
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

7.  Mining gene expression data of multiple sclerosis.

Authors:  Pi Guo; Qin Zhang; Zhenli Zhu; Zhengliang Huang; Ke Li
Journal:  PLoS One       Date:  2014-06-16       Impact factor: 3.240

8.  Peripheral and orofacial pain sensation is unaffected by the loss of p39.

Authors:  Michaela Prochazkova; Bradford Hall; Minghan Hu; Tracy Okine; Jennifer Reukauf; B K Binukumar; Niranjana D Amin; Eva Roque; Harish C Pant; Ashok Kulkarni
Journal:  Mol Pain       Date:  2017 Jan-Dec       Impact factor: 3.395

Review 9.  Inhibitors of Cyclin-Dependent Kinases: Types and Their Mechanism of Action.

Authors:  Paweł Łukasik; Irena Baranowska-Bosiacka; Katarzyna Kulczycka; Izabela Gutowska
Journal:  Int J Mol Sci       Date:  2021-03-10       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.